Vir Biotechnology financials
$10.65+1.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $238.9M | -$29.0K | $64.1M | $240.0K | $1.2M | $3.0M | $12.4M | $2.4M | $3.1M | $56.4M | $16.8M | $2.6M |
| Gross profit | $238.9M | -$29.0K | $64.0M | $251.0K | $1.2M | $3.0M | $11.7M | $2.3M | $3.0M | $56.3M | $16.0M | $2.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 104.6% | 99.1% | 100.0% | 94.5% | 97.9% | 98.3% | 99.9% | 95.2% | 98.6% |
| Operating income | $73.5M | -$132.3M | -$47.9M | -$173.4M | -$118.4M | -$139.5M | -$117.2M | -$231.3M | -$158.6M | -$80.1M | -$139.0M | -$186.7M |
| Net income | $80.1M | -$125.7M | -$42.9M | -$163.1M | -$111.0M | -$121.0M | -$104.6M | -$213.7M | -$138.4M | -$65.3M | -$116.0M | -$163.4M |
| Net margin | 33.5% | 433431.0% | −67.0% | −67975.4% | −9139.9% | −3989.6% | −845.2% | −8979.7% | −4500.1% | −115.8% | −690.9% | −6192.2% |
| Diluted EPS | $0.47 | $-0.85 | $-0.31 | $-1.17 | $-0.80 | $-0.88 | $-0.76 | $-1.56 | $-1.02 | $-0.48 | $-0.86 | $-1.22 |
| EBITDA | $76.3M | -$129.5M | -$45.0M | -$170.4M | -$115.7M | -$136.7M | -$118.2M | -$215.7M | -$128.1M | -$75.6M | -$134.2M | -$178.8M |
| Operating cash flow | $123.3M | -$132.4M | -$25.9M | -$167.6M | -$120.2M | -$78.1M | -$87.6M | -$171.5M | -$77.8M | -$109.4M | -$107.9M | -$155.8M |
| Free cash flow | $123.3M | -$132.8M | -$26.2M | -$167.9M | -$122.8M | -$79.7M | -$89.6M | -$174.2M | -$78.5M | -$111.3M | -$109.5M | -$159.5M |
| Diluted shares | 168.9M | 147.4M | 139.2M | 138.9M | 138.4M | 137.5M | 136.8M | 136.7M | 136.2M | 135.3M | 134.6M | 134.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $278.7M | $274.2M | $232.2M | $170.1M | $211.1M | $273.6M |
| Short-term investments | $254.0M | $202.1M | $234.8M | $336.4M | $394.9M | $528.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.21B | $1.03B | $1.00B | $1.02B | $1.19B | $1.31B |
| Total liabilities | $232.3M | $212.8M | $237.5M | $223.4M | $245.1M | $263.9M |
| Shareholders' equity | $982.5M | $812.8M | $765.3M | $796.1M | $947.5M | $1.04B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology